COMPOSITION:
Vastadin MR Tablet: Each modified release tablet contains Trimetazidine Hydrochloride
BP 35 mg.
PHARMACOLOGY:
Trimetazidine is a unique anti-ischaemic drug, which protects the myocardial cells from
the harmful effects of ischemia. Vastadin MR Tablet (Trimetazidine Hydrochloride) is the
newest twice-daily formulation of the first 3-Keto Acyl Co-A Thiolase inhibitor (KAT), a
metabolic anti-ischemic agent with proven benefits for all coronary patients.
Trimetazidine inhibits the fatty acid pathway by inhibiting 3-Ketoacyl Co-A Thiolase
enzyme and transfers oxygen to glucose pathway. Since glucose pathway is more
efficient in producing energy, the same oxygen produces more energy and makes the
heart more active. Moreover, the aerobic oxidation of glucose stops production of lactic
acid, which prevents angina pectoris.
Trimetazidine has also been proven to provide membrane protection through a large
increase in phospholipids turnover. This effect contributes to a reorganization of fatty
acid utilization balance, resulting in their decreased availability for energy production. As
such, Trimetazidine raises cell tolerance to ischaemia-reperfusion injury. Trimetazidine
enhances the metabolic status of cardiomyocytes in hypoperfused regions in patients
with previous myocardial infarction as well as those with a history of angina